Published in Blood on August 27, 2009
Refined diagnostic criteria and classification of mast cell leukemia (MCL) and myelomastocytic leukemia (MML): a consensus proposal. Ann Oncol (2014) 1.19
Hematopoietic stem-cell transplantation for advanced systemic mastocytosis. J Clin Oncol (2014) 1.14
Systemic mastocytosis with associated clonal hematological non-mast cell lineage disease: clinical significance and comparison of chomosomal abnormalities in SM and AHNMD components. Am J Hematol (2013) 1.09
Targeting cardiac mast cells: pharmacological modulation of the local renin-angiotensin system. Curr Pharm Des (2011) 0.89
Identification of the Ki-1 antigen (CD30) as a novel therapeutic target in systemic mastocytosis. Blood (2015) 0.88
ICON: Eosinophil Disorders. World Allergy Organ J (2012) 0.88
Loss of function of TET2 cooperates with constitutively active KIT in murine and human models of mastocytosis. PLoS One (2014) 0.86
Advanced systemic mastocytosis: the impact of KIT mutations in diagnosis, treatment, and progression. Eur J Haematol (2013) 0.86
ASXL1 but not TET2 mutations adversely impact overall survival of patients suffering systemic mastocytosis with associated clonal hematologic non-mast-cell diseases. PLoS One (2014) 0.85
Advances in the Classification and Treatment of Mastocytosis: Current Status and Outlook toward the Future. Cancer Res (2017) 0.83
Chronic mast cell leukemia: a novel leukemia-variant with distinct morphological and clinical features. Leuk Res (2014) 0.83
Advanced imaging of skeletal manifestations of systemic mastocytosis. Skeletal Radiol (2012) 0.81
Mastocytosis: a paradigmatic example of a rare disease with complex biology and pathology. Am J Cancer Res (2013) 0.80
Systemic mastocytosis associated with chronic myelomonocytic leukemia and xanthogranuloma. Dermatol Pract Concept (2012) 0.80
Systemic mastocytosis associated with splenic marginal zone lymphoma with villous lymphocytes. Dermatol Res Pract (2011) 0.79
Chronic mast cell leukemia (MCL) with KIT S476I: a rare entity defined by leukemic expansion of mature mast cells and absence of organ damage. Ann Hematol (2014) 0.78
Systemic mastocytosis in association with chronic lymphocytic leukemia and plasma cell myeloma. Int J Clin Exp Pathol (2010) 0.77
Eosinophilia in mast cell disease. Immunol Allergy Clin North Am (2014) 0.77
Systemic mastocytosis with associated myeloproliferative neoplasm with t(8;19)(p12;q13.1) and abnormality of FGFR1: report of a unique case. Int J Clin Exp Pathol (2014) 0.75
Mastocytosis: a mutated KIT receptor induced myeloproliferative disorder. Oncotarget (2015) 0.75
Mastocytosis 2016: Updated WHO Classification and Novel Emerging Treatment Concepts. Blood (2016) 0.75
Systemic mastocytosis with associated acute myelogenous leukemia. Proc (Bayl Univ Med Cent) (2014) 0.75
A Case of Intestinal Mastocytosis Misdiagnosed as Crohn's Disease. Case Rep Gastroenterol (2015) 0.75
Systemic Mastocytosis with Smoldering Multiple Myeloma: Report of a Case. Case Rep Oncol Med (2016) 0.75
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood (2009) 23.52
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell (2005) 17.41
A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med (2003) 11.17
Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med (2010) 8.77
New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood (2008) 7.73
MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood (2006) 5.95
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc (2015) 4.70
DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol (2010) 4.18
Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol (2011) 4.06
Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat Rev Cancer (2007) 3.89
Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol (2011) 3.83
The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes. Blood (2005) 3.47
Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. J Clin Oncol (2011) 3.29
The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients. Cancer (2007) 3.28
Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study. Blood (2004) 2.97
Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. Cancer Cell (2008) 2.80
JAK2V617F-mediated phosphorylation of PRMT5 downregulates its methyltransferase activity and promotes myeloproliferation. Cancer Cell (2011) 2.56
Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors. Blood (2009) 2.51
Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases. Blood (2004) 2.40
Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors. Mayo Clin Proc (2006) 2.38
Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders. Blood (2002) 2.34
Host genetic variation contributes to phenotypic diversity in myeloproliferative disorders. Blood (2007) 2.25
The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis. Leuk Res (2009) 2.19
Mesenteric venous thrombosis. Mayo Clin Proc (2013) 2.09
A Pilot Study of the Telomerase Inhibitor Imetelstat for Myelofibrosis. N Engl J Med (2015) 2.08
Early peripheral blood blast clearance during induction chemotherapy for acute myeloid leukemia predicts superior relapse-free survival. Blood (2007) 2.04
FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia. Blood (2004) 1.97
Lenalidomide therapy in myelofibrosis with myeloid metaplasia. Blood (2006) 1.97
Long-term outcome of treatment with ruxolitinib in myelofibrosis. N Engl J Med (2011) 1.96
Tumor suppressor p16 methylation in multiple myeloma: biological and clinical implications. Blood (2006) 1.95
The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients. Blood (2011) 1.93
Phase1/-2 study of Pomalidomide in myelofibrosis. Am J Hematol (2010) 1.90
Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. J Clin Oncol (2011) 1.88
Advances in understanding and management of myeloproliferative neoplasms. CA Cancer J Clin (2009) 1.87
A CK2-dependent mechanism for activation of the JAK-STAT signaling pathway. Blood (2011) 1.84
Nonhepatosplenic extramedullary hematopoiesis: associated diseases, pathology, clinical course, and treatment. Mayo Clin Proc (2003) 1.82
The JAK2(V617F) tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates. Br J Haematol (2005) 1.82
JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance. Br J Haematol (2005) 1.81
Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis). Blood (2012) 1.77
Intensive care unit support and Acute Physiology and Chronic Health Evaluation III performance in hematopoietic stem cell transplant recipients. Crit Care Med (2003) 1.76
SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value. Blood (2011) 1.73
Pulmonary complications in adult blood and marrow transplant recipients: autopsy findings. Chest (2005) 1.72
Selective inhibition of JAK2-driven erythroid differentiation of polycythemia vera progenitors. Cancer Cell (2008) 1.71
Prevalence and prognostic impact of allelic imbalances associated with leukemic transformation of Philadelphia chromosome-negative myeloproliferative neoplasms. Blood (2010) 1.70
Cytoreductive therapy in 108 adults with systemic mastocytosis: Outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine. Am J Hematol (2009) 1.69
Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: a collaborative study of 1027 patients. Am J Hematol (2014) 1.65
Antithymocyte globulin has limited efficacy and substantial toxicity in unselected anemic patients with myelodysplastic syndrome. Blood (2002) 1.64
Anemia in the elderly: how should we define it, when does it matter, and what can be done? Mayo Clin Proc (2007) 1.64
The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera. Cancer (2006) 1.64
Myeloproliferative neoplasms cause glomerulopathy. Kidney Int (2011) 1.62
Mutations and thrombosis in essential thrombocythemia: prognostic interaction with age and thrombosis history. Eur J Haematol (2014) 1.58
Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. J Clin Oncol (2012) 1.58
Myelodysplastic syndrome and acute myeloid leukemia after autotransplantation for lymphoma: a multicenter case-control study. Blood (2002) 1.57
Concomitant neutrophil JAK2 mutation screening and PRV-1 expression analysis in myeloproliferative disorders and secondary polycythaemia. Br J Haematol (2005) 1.56
Development of myelodysplastic syndrome evolving to acute myeloid leukemia in a patient receiving etanercept for psoriasis. J Am Acad Dermatol (2011) 1.54
Long-term outcome of allogeneic stem cell transplantation in chronic lymphocytic leukemia: analysis after a minimum follow-up of 5 years. Leuk Lymphoma (2008) 1.53
Durable responses to thalidomide-based drug therapy for myelofibrosis with myeloid metaplasia. Mayo Clin Proc (2004) 1.52
Eosinophils are derived from the neoplastic clone in patients with systemic mastocytosis and eosinophilia. Leuk Res (2003) 1.50
Neutropenic colitis after treatment of acute myelogenous leukemia with idarubicin and cytosine arabinoside. Mayo Clin Proc (2002) 1.47
SRSF2 mutations in primary myelofibrosis: significant clustering with IDH mutations and independent association with inferior overall and leukemia-free survival. Blood (2012) 1.46
Clinical correlates of JAK2V617F allele burden in essential thrombocythemia. Cancer (2007) 1.46
Host immunity affects survival in myelodysplastic syndromes: Independent prognostic value of the absolute lymphocyte count. Am J Hematol (2010) 1.46
Peripheral blood stem cell transplantation in 16 patients with POEMS syndrome, and a review of the literature. Blood (2004) 1.45
Polyclonal immunoglobulin free light chain levels predict survival in myeloid neoplasms. J Clin Oncol (2012) 1.44
Hematological manifestations of copper deficiency: a retrospective review. Eur J Haematol (2008) 1.43
LNK mutations in JAK2 mutation-negative erythrocytosis. N Engl J Med (2010) 1.43